Edge Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
$583K Buy
34,000
+8,000
+31% +$139K ﹤0.01% 261
2016
Q4
$466K Hold
26,000
﹤0.01% 269
2016
Q3
$541K Buy
26,000
+3,000
+13% +$74.4K ﹤0.01% 260
2016
Q2
$618K Hold
23,000
0.01% 258
2016
Q1
$623K Buy
23,000
+2,000
+10% +$53.6K 0.01% 261
2015
Q4
$610K Hold
21,000
0.01% 271
2015
Q3
$570K Hold
21,000
0.01% 270
2015
Q2
$575K Buy
21,000
+11,400
+119% +$320K 0.01% 269
2015
Q1
$256K Hold
9,600
﹤0.01% 291
2014
Q4
$203K Sell
9,600
-1,800
-16% -$40.2K ﹤0.01% 296
2014
Q3
$271K Hold
11,400
﹤0.01% 297
2014
Q2
$263K Sell
11,400
-1,600
-12% -$35.3K ﹤0.01% 296
2014
Q1
$297K Hold
13,000
﹤0.01% 293
2013
Q4
$240K Buy
+13,000
New +$227K ﹤0.01% 299

Other funds holding NVO

Edge Asset Management's NVO Position: Q1 2017 in Review

Edge Asset Management increased its Novo Nordisk (NVO) stake by 31% in Q1 2017, buying an estimated $139K and bringing the position to 34,000 shares worth $583K. The position accounts for ﹤0.01% of the portfolio, ranked #261.

Edge Asset Management first reported a position in NVO in Q4 2013 and has held it in 14 quarters since. The position peaked at $623K in Q1 2016. 463 funds tracked by Wall St. Rank hold NVO as of Q1 2017.

  • Edge Asset Management held 34,000 shares of Novo Nordisk worth $583K as of Q1 2017.
  • Edge Asset Management bought 8,000 Novo Nordisk shares in Q1 2017, an estimated $139K.
  • Novo Nordisk made up ﹤0.01% of Edge Asset Management's portfolio in Q1 2017, its #261 holding.
  • Edge Asset Management first reported a position in Novo Nordisk in Q4 2013 and has held it in 14 quarters since.
  • Edge Asset Management's Novo Nordisk position peaked at $623K in Q1 2016.
  • 463 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2017.

Based on Edge Asset Management's 13F filing for Q1 2017, filed 11 May 2017.